title: [Management of subretinal hemorrhage with r-TPA, SF-6 and ranibizumab].
abstract: METHODS
  We present a case of a patient with subretinal hemorrhage treated with intravitreal r-TPA, SF-6 and ranibizumab.
  
  
  CONCLUSIONS
  Subretinal hemorrhages secondary to age-related macular degeneration are associated with poor visual outcome. A wide variety of management approaches has been developed, but the prognosis of these patients has not been modified by any of them. The association of an intravitreal anti VEGF drug to r-TPA and gas, may improve its results as we add the treatment of the subjacent etiology to the pneumatic displacement.
authors.affiliation: Licenciado en Medicina, Universidad Complutense de Madrid, Servicio de Oftalmología, Hospital Príncipe de Asturias, Madrid, España. juangros@gmail.com
authors.forename: J
authors.initials: J
authors.lastname: Gros-Otero
authors.forename: J
authors.initials: J
authors.lastname: Benítez-Herreros
authors.forename: C
authors.initials: C
authors.lastname: Beckford-Torngren
authors.forename: C
authors.initials: C
authors.lastname: Cámara-González
authors.forename: M
authors.initials: M
authors.lastname: Castro-Rebollo
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000150:complications; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D004630:Emergencies; D006801:Humans; D056965:Injections, Intraocular; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D008297:Male; D019152:Paracentesis; D000069579:Ranibizumab; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D012166:Retinal Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D013459:Sulfur Hexafluoride / Q000627:therapeutic use*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator; D013459:Sulfur Hexafluoride; D000069579:Ranibizumab